INNOVACAP vs JUBLPHARMA: Stock Comparison
JUBILANT PHARMOVA is the larger company by market capitalisation. INNOVA CAPTAB shows a higher ROE, faster revenue growth and lower leverage, while JUBILANT PHARMOVA shows a lower P/E and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
INNOVACAP leads 8; JUBLPHARMA leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | INNOVACAP | JUBLPHARMA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | INNOVACAP | JUBLPHARMA |
|---|---|---|
| Live Price | ₹1,175.4 | ₹924.5 |
| Day Change | 4.44% | 1.83% |
| Volume | 3.22 L | 4.98 L |
| 52-Week High | ₹1,155.8 | ₹1,183 |
| 52-Week Low | ₹622 | ₹786.05 |
| Distance from 52W High | 1.7% | -21.85% |
Valuation
| Metric | INNOVACAP | JUBLPHARMA |
|---|---|---|
| Market Cap | ₹6,760 Cr | ₹14,774 Cr |
| P/E Ratio | 41.02x | 40.9x |
| P/B Ratio | 5.93x | 2.03x |
| EPS | ₹5.6 | ₹3.55 |
| Book Value | ₹188.99 | ₹445.48 |
| Dividend Yield | 0.17% | 0.57% |
Growth
| Metric | INNOVACAP | JUBLPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 42.3% | 18.7% |
| EPS Growth (TTM YoY) | 28.6% | -22.4% |
| Qtr Sales Growth | -14.95% | 3,222.5% |
| Qtr Profit Growth | -27.34% | 672.6% |
Profitability & Leverage
| Metric | INNOVACAP | JUBLPHARMA |
|---|---|---|
| ROE | 12.92% | 5.6% |
| ROCE | 10.73% | 6.19% |
| Net Margin | 8.65% | 5.28% |
| Operating Margin | 12.59% | 9.98% |
| Debt to Equity | 0.32x | 0.45x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | INNOVACAP | JUBLPHARMA |
|---|---|---|
| Promoter Holding | 50.9% | 44.39% |
| FII Holding | 0.34%▲ 0.11 pp | 15.87%▼ 0.03 pp |
| DII Holding | 19.92%▼ 0.22 pp | 12.4%▲ 0.78 pp |
| Public Holding | 28.84%▲ 0.11 pp | 23.5%▼ 0.74 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INNOVA CAPTAB and JUBILANT PHARMOVA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.